In a pre-specified sub-group analysis of the GLOBAL LEADERS trial, the risk of all-cause death, cardiac death, patient-oriented composite endpoint, ischemic stroke, any MI, and any revascularization were significantly higher in non-insulin treated diabetic patients than non-diabetics; of interest, the risk of adverse events was even higher in insulin-treated diabetics [25]. The gene discussed is INS; the disease is ischemic stroke.